Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3(mut+)) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the phase III ADMIRAL trial Meeting Abstract
| Authors: | Perl, A. E.; Martinelli, G.; Cortes, J. E.; Neubauer, A.; Berman, E.; Paolini, S.; Montesinos, P.; Baer, M. R.; Larson, R. A.; Ustun, C.; Fabbiano, F.; Di Stasi, A.; Stuart, R.; Olin, R.; Kasner, M.; Ciceri, F.; Chou, W. C.; Podoltsev, N.; Recher, C.; Yokoyama, H.; Hosono, N.; Yoon, S. S.; Lee, J. H.; Pardee, T.; Fathi, A. T.; Liu, C.; Liu, X.; Bahceci, E.; Levis, M. J. |
| Abstract Title: | Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3(mut+)) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the phase III ADMIRAL trial |
| Meeting Title: | 110th Annual Meeting of the American Association for Cancer Research (AACR) |
| Journal Title: | Cancer Research |
| Volume: | 79 |
| Issue: | 13 Suppl. |
| Meeting Dates: | 2019 Mar 29-Apr 3 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2019-07-01 |
| Language: | English |
| ACCESSION: | WOS:000488129900164 |
| DOI: | 10.1158/1538-7445.Am2019-ct184 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: CT184 -- Source: Wos |
